|
1. Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K. The role of angiogenesis in solid tumors: an over-view. Eur J Intern Med 2009; 20(7): 663-71. 2. Drevs J. VEGF and angiogenesis: imlications for breast cancer therapy. EJC Supplements 2008; 6: 7-13. 3. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001; 33(4): 409–20. 4. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62(14): 4123–31. 5. Bates DO, MacMillan PP, Manjaly JG, Qiu Y, Hudson SJ, Bevan HS, et al. The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term. Clin Sci (Lond) 2006; 110(5): 575 –85. 6. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to the human chromosome 6p21.3. Circulation 1996; 93(8): 1493–5. 7. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437(2): 169–83. 8. Eichmann A, Simons M. VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol 2012; 24(2): 188–93. 9. Carmeliet P, Ruiz de Almodovar C. VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration. Cell Mol Life Sci 2013; 70(10): 1763–78. 10. Huez I, Bornes S, Bresson D, Creancier L, Prats H. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 2001; 15(12): 2197–210. 11. Meiron M, Anunu R, Scheinman EJ, Hashmueli S, Levi BZ. New isoforms of VEGF are translated from alternative initiation CUG codons located in its 5’UTR. Biochem Biophys Res Commun 2001; 282(4): 1053–60. 12. Tee MK, Jaffe RB. A precursor form of vascular endothelial growth factor arises by initiation from an upstream in-frame CUG codon. Biochem J 2001; 359 (Pt 1): 219–26. 13. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267(36): 26031–7. 14. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002; 16(20): 2684–98. 15. Gu F, Li X, Kong J, Pan B, Sun M, Zheng L, et al. VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis. Biochem Biophys Res Commun 2013; 441(1): 18–24 16. Dvorak HF. VPF/VEGF and the angiogenic response. Semin Perinatol 2000; 24(1): 75–8. 17. Raab S, Plate KH. Different networks, common growth factors: shared growth factors and receptors of the vascular and nervous system. Acta Neuropathol 2007; 113(6): 607-26. 18. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under phisiological and pathological conditions. Clin Sci 2005; 109(3): 227-41. 19. Emamgholipour S, Bandehpour M, Shabani P, Maghen L, Yaghmaee B, Kazemi B. Mutagenesis in se-quence encoding of human factor VII for gene therapy of hemophilia. DARU 2009; 17(4): 294-8. 20. Rennel E, Waine E, Guan H, Schüler Y, Leenders W, Woolard J, et al. The endogenous antiangiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 2008; 98(7): 1250–7. 21. Stalmans I, Ng YS, Rohan R, Fruttiger M, Bouche A, Yuce A, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002; 109(3): 327–36. 22. Gerhardt H. VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 2008; 4(4): 241–6. 23. von Degenfeld G, Banfi A, Springer ML, Wagner RA, Jacobi J, Ozawa CR, et al. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. FASEB J 2006; 20(14): 2657–9. 24. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21(3): 505-15. 25. Walter DH1, Hink U, Asahara T, Van Belle E, Horowitz J, Tsurumi Y, et al. The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation. Lab Invest 1996; 74(2): 546–56. 26. Chen E, Hermanson S, Ekker SC. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood 2004; 103(5): 1710–9. 27. Wijelath ES, Rahman S, Namekata M, Murray J, Nishimura T, Mostafavi-Pour Z, et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 2006; 99(8): 853–60. 28. Krilleke D, DeErkenez A, Schubert W, Giri I, Robinson GS, Ng YS, et al. Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. J Biol Chem 2007; 282(38): 28045–56. 29. Ruiz de AC, Coulon C, Salin PA, Knevels E, Chounlamountri N, Poesen K. Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1. J Neurosci 2010; 30(45): 15052–66. 30. Chen S, Chakrabarti R, Keats EC, Chen M, Chakrabarti S, Khan ZA. Regulation of vascular endothelial growth factor expression by extra domain B segment of fibronectin in endothelial cells. Invest Ophthalmol Vis Sci 2012; 53(13): 8333–43.
|
.png){kind=logo}
